Menopause Hair Loss: Why Hair Thins in Perimenopause and After, and What the Studies Show
Start with our pillar guide: What Is the Skin Barrier? The Science of Hydration, Ceramides and Occlusives, or browse all Skincare Fundamentals articles.
Menopause hair loss is common. In one Thai study, 52.2% of 178 postmenopausal women evaluated had female pattern hair loss. Reviews link perimenopause hair loss to falling estrogen and a relative rise in androgens, but hair density also falls with age. Topical minoxidil has the strongest trial evidence, though no treatment trial we reviewed selected menopausal women.
Evidence: Limited.
This guide is part of our series on menopause skin care, and the series hub, the menopause skin care guide, covers skin changes more broadly. Here we look only at scalp hair: why it thins, which types of loss show up around menopause, what treatment and hormone studies report, and where peptide serums fit.
Key takeaways
- A 2022 cross-sectional study recruited 200 postmenopausal Thai women aged 50–65 and evaluated 178 of them. Of those, 52.2% had female pattern hair loss, and after adjustment only a BMI of 25 or more stayed linked to it (Chaikittisilpa et al., 2022).
- A 2011 review summarizes a study in which hair density fell with age but did not track menopausal status (Mirmirani, 2011).
- A 2016 Cochrane review of 47 trials (5,290 women) found that topical minoxidil gave more women moderate to marked regrowth than placebo (risk ratio 1.93, moderate-quality evidence). The trials did not select menopausal women (van Zuuren et al., 2016).
- Two reviews state that hormone therapy is not indicated for hair loss alone (Zouboulis et al., 2022; Lee et al., 2026).
- Frontal fibrosing alopecia is a scarring hair loss that mainly affects postmenopausal women. It pushes the hairline back and often thins the eyebrows (Alenezi et al., 2026).
Why does hair thin during perimenopause and menopause?
Reviews link the thinning to hormone shifts: ovarian estrogen production stops, and androgens rise relative to it. Aging also plays a part, and one study found that density tracked age rather than menopause itself.
Hormones can start fluctuating up to 10 years before menopause, according to a 2025 narrative review in Maturitas. The review describes the hair follicle as estrogen-sensitive and connects the transition to lower hair density, thinner strands (lower caliber) and changes in texture. It also notes the emotional cost, including stress, anxiety and lower self-esteem (Gupta et al., 2025). One author of that review has received clinical trial grants from Amgen, Sun Pharmaceuticals, Eli Lilly, Incyte and Pfizer and consults for NeoGenesis.
A 2022 literature review found fewer anagen hairs in postmenopausal women. Anagen is the growth phase of the hair cycle. The authors conclude that more research is needed on treatment targets and on the role of hormonal therapy (Kamp et al., 2022). They declare no conflicts of interest.
A 2011 review complicates the hormone story. It summarizes a study of pre- and postmenopausal women without alopecia. Menopausal status affected growth rate, the share of hairs in anagen and hair diameter, most of all at the front of the scalp. Hair density, however, fell with age and did not correlate with menopausal status. The changes were most noticeable in the mid-forties (Mirmirani, 2011).
Nobody yet knows the exact mechanism. A 2025 Nature Reviews Disease Primers overview of androgenetic alopecia, the medical name for pattern hair loss, says postmenopausal women are susceptible but "the molecular basis of AGA in women remains undetermined" (Liu et al., 2025). Its authors disclose hair-loss patent applications and ties to Amplifica, L'Oréal, Oddity, DS Laboratories, Olaplex, Eli Lilly, Pfizer and others.
Evidence: Limited (reviews and one summarized observational study).
How common is menopause hair loss?
It's common, but the best number comes from one study. Among 178 postmenopausal Thai women evaluated, 52.2% had female pattern hair loss (95% CI 44.6–59.8).
That cross-sectional study recruited 200 women aged 50–65 and excluded anyone with recent hair loss treatment. On average the women were 58.8 years old and 9.2 years past menopause. Three dermatologists confirmed the diagnosis using standardized photos and trichoscopy, a magnified scalp exam. Most cases were mild, Ludwig grade I. Age, time since menopause and BMI were each linked to hair loss at first. After adjusting for age and family history, only a BMI of 25 or more remained significant (adjusted odds ratio 2.65). No conflicts were reported (Chaikittisilpa et al., 2022).
Post menopausal hair loss in one cohort
- had female pattern hair loss
- 52.2%
- of cases were Ludwig grade I
- 73.2%
- average time since menopause
- 9.2 years
- adjusted odds ratio for BMI 25 or higher
- 2.65
Show data table
| Ludwig grade | Share of cases (%) |
|---|---|
| Grade I (mild) | 73.2% |
| Grade II | 22.6% |
| Grade III (most severe) | 4.3% |
Read these figures as one estimate. The study covered a single Thai population at one point in time, so it can't show what caused the hair loss or how common it is elsewhere. A 2026 systematic review of 40 studies backs up the general pattern. Alopecia, mainly frontal fibrosing alopecia and female pattern hair loss, had the strongest postmenopausal associations of the skin conditions it examined, and earlier or surgical menopause was linked to greater risk (Roster et al., 2026). One author discloses chairing the AAD Menopause and Women's Health in Dermatology Quality Improvement Workgroup; the others report no conflicts.
Evidence: Limited for the prevalence figure; Moderate for the association.
What type of menopause hair loss is it?
Three patterns show up most often in reviews: female pattern hair loss, diffuse shedding (telogen effluvium) and frontal fibrosing alopecia. Their descriptions differ, but only a clinician can tell which one you have.
- Female pattern hair loss (FPHL). A 2020 review describes diffuse thinning over the central scalp with the front hairline usually kept. It also notes that only about a third of women with this pattern have abnormal androgen levels (Starace et al., 2020).
- Telogen effluvium. This is diffuse shedding, which a 2025 review lists among the disorders seen more often after menopause (Gupta et al., 2025).
- Frontal fibrosing alopecia (FFA). A 2026 CME review describes FFA as a scarring alopecia that mainly affects postmenopausal women. The frontotemporal hairline slowly recedes into a hairless band, often with eyebrow and body hair loss (Alenezi et al., 2026). In a scarring alopecia, follicles are replaced by scar tissue. Both of these JAAD FFA reviews share one author who is an investigator for Lilly and Ergomed and a consultant for Pfizer.
Some women notice the opposite change on the face. A 2022 review lists more unwanted facial hair among menopausal hair symptoms, along with lower scalp density and changes in hair quality (Zouboulis et al., 2022). One of that review's authors lists an affiliation with Laboratoires Vichy, and PubMed shows no conflict statement.
Evidence: Expert opinion (reviews).
Menopause hair loss treatment: what does the evidence show?
Topical minoxidil has the most trial evidence for female pattern hair loss in general. No treatment trial in the abstracts we reviewed selected menopausal women, so every result below is borrowed from broader groups.
| Topical minoxidil vs placebo (van Zuuren, Cochrane 2016) | 47 RCTs, 5,290 women with FPHL (17 trials on minoxidil) | 24–32 weeks (minoxidil outcomes, per full text) | Not given here | More women reported moderate to marked regrowth (RR 1.93). Evidence: Moderate (not menopause-selected) |
| Oral vs topical minoxidil (Sobral, 2025) | 4 RCTs, 279 patients with androgenetic alopecia | 24-39 weeks follow-up | Not given here | Similar in 4 small trials; more unwanted body hair with oral (RR 2.01). Evidence: Limited |
| Oral anti-androgens (Starace review, 2020) | Review | Not applicable | Not given here | Named as a main drug class, alongside topical minoxidil. Evidence: Expert opinion |
| Microneedling as an adjunct (English, 2022) | 22 studies, 1,127 subjects | Varied | Not given here | Improved hair parameters when added to other treatments. Evidence: Limited |
Topical minoxidil vs placebo (van Zuuren, Cochrane 2016)
Result: More women reported moderate to marked regrowth (RR 1.93). Evidence: Moderate (not menopause-selected)
Pooled data showed more self-reported regrowth with minoxidil than placebo (moderate quality) and about 13 more hairs per cm² (low quality). Adverse events did not differ significantly from placebo. Two strengths showed no difference in effect. Authors declare no conflicts.
Oral vs topical minoxidil (Sobral, 2025)
Result: Similar in 4 small trials; more unwanted body hair with oral (RR 2.01). Evidence: Limited
No difference in hair density or diameter. The abstract does not split results by sex. Funding and conflicts not stated in PubMed.
Oral anti-androgens (Starace review, 2020)
Result: Named as a main drug class, alongside topical minoxidil. Evidence: Expert opinion
Prescription only. Finasteride and spironolactone belong in this discussion with a dermatologist. The Cochrane review found finasteride no more effective than placebo (low-quality evidence), and its authors call for more trials of both.
Microneedling as an adjunct (English, 2022)
Result: Improved hair parameters when added to other treatments. Evidence: Limited
Study quality was low (Jadad scores 1-3). No serious adverse events in 657 treated subjects. All authors are affiliated with Perfect Hair Health, a commercial hair-loss company.
No row tests a menopause-selected group in the abstracts we reviewed.
Minoxidil. The 2016 Cochrane review pooled 6 studies: 157 of 593 women on minoxidil reported moderate to marked regrowth, compared with 77 of 555 on placebo (moderate-quality evidence). Hair counts rose by 13.18 hairs per cm² over placebo, though that figure is low quality. Trials comparing two strengths found no difference between them (van Zuuren et al., 2016). A 2025 meta-analysis found oral and topical minoxidil similar in 4 small trials. Hypertrichosis, meaning extra hair growth elsewhere on the body, was more common with oral minoxidil (Sobral et al., 2025). Ask a dermatologist before using either form.
Anti-androgens. A 2020 review names oral anti-androgens as a main drug class for this pattern (Starace et al., 2020). Finasteride and spironolactone are examples; the 2016 Cochrane review found finasteride no more effective than placebo (low-quality evidence) (van Zuuren et al., 2016). These are prescription decisions for a dermatologist.
Microneedling. Microneedling makes tiny skin punctures with fine needles. A 2022 systematic review found it improved hair parameters as an add-on to other treatments, but the authors rate the data as relatively low quality, and all of them work for a commercial hair-loss company (English et al., 2022).
Evidence: Moderate for minoxidil in FPHL generally; Limited for everything else; no menopause-selected trial.
HRT and hair loss: what have studies found?
Reviews state that hormone therapy is not indicated for hair loss alone. In the abstracts we reviewed, the evidence connecting HRT to hair is at the review level only, and no randomized trial measured scalp hair as an outcome.
A 2022 Climacteric review says HRT is not indicated for skin and hair symptoms alone because of the balance of risks and benefits. It adds that possible skin and hair effects can be part of a broader conversation with women about their menopause care (Zouboulis et al., 2022). A 2026 narrative review written for trichologists, specialists in hair and scalp, reaches the same conclusion: HRT "is not currently indicated for hair loss alone" (Lee et al., 2026). Those authors also give their own views on particular hormone forms. Those views are not trial results, and PubMed shows no funding or conflict statement for the review. Since HRT isn't used for hair alone, no particular HRT can be called "best" for hair.
Some gaps are specific:
- Progesterone. A 2021 comprehensive review found no study of micronized progesterone and menopausal scalp hair (Gasser et al., 2021).
- Testosterone. A 2019 meta-analysis of 36 randomized trials (8,480 women) found testosterone was linked to more reports of acne and hair growth. The abstract doesn't say which body site, and no serious adverse events were recorded. Australia's National Health and Medical Research Council funded it (Islam et al., 2019). The acne side of hormone shifts is covered in our perimenopause acne guide.
- Hormone therapy and FFA. The 2026 systematic review linked menopausal hormone therapy with a higher risk of frontal fibrosing alopecia. It notes that most of the studies used formulations less common in current practice (Roster et al., 2026).
Topical hormones for the face are a separate subject. Our guide to estrogen cream for the face covers a topical product for facial skin, and it isn't a hair treatment. Hormone decisions depend on your whole health picture, so ask your clinician.
Evidence: Expert opinion (reviews); indirect for testosterone.
Do peptides help menopause hair loss?
We don't know. In the abstracts we reviewed, no peptide hair trial selected menopausal women, and the evidence for cosmetic hair actives is small and mostly industry-linked.
A 2025 review in the International Journal of Trichology looked at 24 articles and technical files on popular topical actives, including Redensyl, Procapil, Capixyl, Baicapil, AnaGain and rosemary oil. Most were tested in combination formulas, with small samples, no comparison against standard therapy, the type of alopecia often not stated, and conflicts of interest. The author sees a possible role as an add-on, or for people who can't tolerate standard treatment, and declares no conflicts (Bikash, 2025). A 2025 primer lists hair follicle-activating peptides as an emerging therapy, which means they aren't established (Liu et al., 2025).
We've reviewed the individual peptide trials elsewhere. See our evidence review of peptides for hair growth, our guide to copper peptides for hair, and our The Ordinary hair density serum review for one product.
Evidence: Limited / Early.
What gentle hair care helps while it's thinning?
No study in the abstracts we reviewed tested hair-care habits for menopause hair loss. The steps below are dermatology convention, not trial findings.
Gentle hair care habits (all expert opinion)
- StylingChoose low-tension styles
Looser ponytails, buns and braids pull less on follicles than tight ones. Evidence: Expert opinion.
- DryingUse less heat
Air-dry when you can, or use a lower dryer setting. Evidence: Expert opinion.
- DetanglingHandle wet hair gently
Use a wide-tooth comb and work from the ends upward. Evidence: Expert opinion.
- TrackingNote changes
Photos of your part and hairline taken in the same light make changes easier to show a dermatologist. Evidence: Expert opinion.
Some reviews list cosmetic products, including sunscreen, hair care products and moisturizers, among implicated triggers of frontal fibrosing alopecia. That link is an association and hasn't been shown to cause FFA (Ezzat et al., 2026). If you're worried about FFA, the dermatologist who examines you is the right person to ask.
Evidence: Expert opinion.
When should you see a dermatologist about menopause hair loss?
See a dermatologist when hair loss is sudden, patchy, affects the hairline or eyebrows, or comes with scalp symptoms or other health changes. A scarring cause like FFA progresses slowly, and early assessment is how it gets caught.
Reasons to book a visit:
- Sudden or heavy shedding
- A receding hairline at the front or temples, or eyebrow loss
- Bald patches
- Scalp redness, itch, burning or scaling
- Hair loss alongside other symptoms, such as acne, irregular bleeding or unwanted facial hair
A 2020 review says the diagnosis is usually made in clinic, with trichoscopy showing miniaturized hairs. A blood test can reveal signs of excess androgens, such as polycystic ovary syndrome. A scalp biopsy can help when the picture is unclear or a scarring alopecia is suspected (Starace et al., 2020). Which tests you need is your clinician's call. The FFA management review notes that no established monitoring guidelines exist yet (Ezzat et al., 2026).
Evidence: Expert opinion (reviews).
Part of our menopause skin series
This article belongs to our menopause skin series. The hub, the menopause skin care guide, covers skin changes and ingredients. See our menopause itchy skin guide. See our peptides for menopause guide. See our perimenopause acne guide.
Where the evidence stops
In the abstracts we reviewed, no randomized trial tested any hair treatment in a menopause-selected group. The minoxidil results come from women with female pattern hair loss at any age. The evidence linking HRT to hair is review-level only, and one review found no study of progesterone and menopausal scalp hair. The best prevalence figure comes from one Thai cohort, and the main age-versus-menopause finding comes from one study summarized in a review. Peptide serums have no menopause-specific trial. We need longer trials that enroll perimenopausal and postmenopausal women and report hair outcomes by hormone status.
FAQ
Is hair loss normal in perimenopause?
Hair thinning is common around menopause. A Thai study found female pattern hair loss in 52.2% of 178 postmenopausal women evaluated, and reviews describe hair changes starting during the transition. Common doesn't mean it shouldn't be checked: sudden shedding, patches or a receding hairline are reasons to see a dermatologist.
Does menopause hair loss grow back?
It depends on the type. Female pattern hair loss doesn't scar, and minoxidil trials in women with it reported more regrowth than placebo. Frontal fibrosing alopecia is a scarring type, and reviews focus on stabilizing it. In the abstracts we reviewed, no study followed regrowth in menopausal women specifically.
Does HRT help hair loss?
Reviews state that hormone therapy is not indicated for hair loss alone. In the abstracts we reviewed, no randomized trial measured scalp hair as an outcome of menopausal hormone therapy. Ask your clinician how hormone therapy fits your own symptoms.
Can HRT cause hair loss?
The evidence is review-level. A 2026 systematic review linked menopausal hormone therapy with a higher risk of frontal fibrosing alopecia, mostly in older formulations. A meta-analysis of 36 testosterone trials found more reports of hair growth and acne but didn't say where the hair grew. Ask your clinician about your own situation.
Does minoxidil work for menopausal hair loss?
A Cochrane review of 47 trials found that, in female pattern hair loss, topical minoxidil gave more women moderate to marked regrowth than placebo (moderate-quality evidence). Those trials didn't select menopausal women. Ask a dermatologist before using it.
Do peptide serums help menopause hair loss?
We don't know yet. In the abstracts we reviewed, no peptide hair trial selected menopausal women. A 2025 review found cosmetic hair actives were tested mostly in small, combination-formula studies, many with conflicts of interest.
What shampoo is best for menopausal hair?
No study in the abstracts we reviewed tested a shampoo for menopausal hair loss, so there's no evidence-based best shampoo. Picking a gentle, non-irritating one is expert opinion. Some reviews list hair care products among possible triggers of frontal fibrosing alopecia, though that link is an association, not proof.
When should I see a dermatologist about menopause hair loss?
See a dermatologist for sudden heavy shedding, a receding hairline, eyebrow loss, bald patches, scalp redness or itch, or hair loss alongside other symptoms. The clinician decides whether you need blood tests or a scalp biopsy.
References
- Chaikittisilpa, et al. Prevalence of female pattern hair loss in postmenopausal women: a cross-sectional study. Menopause. 2022. Cross-sectional study, 200 recruited and 178 evaluated, postmenopausal women aged 50–65 in Thailand; tagged as non-US government research support; conflicts "none reported." https://pubmed.ncbi.nlm.nih.gov/35357365/
- Gupta, et al. Menopause and hair loss in women: Exploring the hormonal transition. Maturitas. 2025. Narrative review; one author reports clinical trial grants from Amgen, Sun Pharmaceuticals, Eli Lilly, Incyte and Pfizer and consults for NeoGenesis. https://pubmed.ncbi.nlm.nih.gov/40318238/
- Kamp, et al. Menopause, skin and common dermatoses. Part 1: hair disorders. Clin Exp Dermatol. 2022. Literature review; authors declare no conflicts of interest. https://pubmed.ncbi.nlm.nih.gov/35796569/
- Mirmirani. Hormonal changes in menopause: do they contribute to a 'midlife hair crisis' in women? Br J Dermatol. 2011. Review summarizing a study of pre- and postmenopausal women; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/22171679/
- Liu, et al. Androgenetic alopecia. Nat Rev Dis Primers. 2025. Review (primer); authors disclose hair-loss patent applications (University of California, Irvine) and ties to Amplifica, L'Oréal, Oddity Labs, DS Laboratories, Olaplex, Eli Lilly, Pfizer and others. https://pubmed.ncbi.nlm.nih.gov/41068174/
- Roster, et al. Menopause and Common Dermatoses: A Systematic Review. Am J Clin Dermatol. 2026. Systematic review of 40 studies; one author discloses chairing the AAD Menopause and Women's Health in Dermatology Quality Improvement Workgroup; the others report no conflicts; no funding received. https://pubmed.ncbi.nlm.nih.gov/41331233/
- Zouboulis, et al. Skin, hair and beyond: the impact of menopause. Climacteric. 2022. Narrative review; one author lists a Laboratoires Vichy affiliation; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/35377827/
- Starace, et al. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am J Clin Dermatol. 2020. Review with guideline aims; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/31677111/
- Alenezi, et al. Frontal fibrosing alopecia part I - Diagnosis and clinical presentation. J Am Acad Dermatol. 2026. CME review; one author is an investigator for Lilly and Ergomed Clinical Research and a consultant for Pfizer. https://pubmed.ncbi.nlm.nih.gov/39824360/
- Ezzat, et al. Frontal fibrosing alopecia part II: Etiopathogenesis and management. J Am Acad Dermatol. 2026. CME review; one author is an investigator for Lilly and Ergomed Clinical Research and a consultant for Pfizer. https://pubmed.ncbi.nlm.nih.gov/39800209/
- van Zuuren, et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016. Systematic review and meta-analysis, 47 RCTs, 5,290 women with FPHL, not menopause-selected; tagged as non-US government research support; authors declare no conflicts. https://pubmed.ncbi.nlm.nih.gov/27225981/
- Sobral, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol. 2025. Meta-analysis, 4 RCTs, 279 patients, 24–39 weeks follow-up; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/39425514/
- English, et al. Microneedling and Its Use in Hair Loss Disorders: A Systematic Review. Dermatol Ther (Heidelb). 2022. Systematic review, 22 studies, 1,127 subjects, Jadad scores 1–3; all authors affiliated with Perfect Hair Health, a commercial hair-loss company; authors declare nothing to disclose and no funding (per full text). https://pubmed.ncbi.nlm.nih.gov/34854067/
- Lee, et al. Hormone Replacement Therapy and Hair: A Review for Trichologists Treating Menopausal Women. Dermatology. 2026. Narrative review; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/41719205/
- Gasser, et al. Impact of progesterone on skin and hair in menopause - a comprehensive review. Climacteric. 2021. Comprehensive review, 6 studies identified, none on scalp hair; funding and conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/33527841/
- Islam, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019. Systematic review and meta-analysis, 36 RCTs, 8,480 women; funded by the Australian National Health and Medical Research Council (per abstract). https://pubmed.ncbi.nlm.nih.gov/31353194/
- Bikash. Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology. 2025. Review of 24 articles and technical files; author declares no conflicts of interest. https://pubmed.ncbi.nlm.nih.gov/40654553/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Menopause and hormone decisions are personal. Ask your clinician about hormone therapy, prescription creams or any new skin symptom.